Avelumab Versus Docetaxel in Patients With Platinum-Treated Advanced NSCLC: 2-Year Follow-Up From the JAVELIN Lung 200 Phase 3 Trial
Journal
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
Journal Volume
16
Journal Issue
8
Pages
1369
Date Issued
2021
Author(s)
Park, Keunchil
Özgüroğlu, Mustafa
Vansteenkiste, Johan
Spigel, David
Ishii, Hidenobu
Garassino, Marina
de Marinis, Filippo
Szczesna, Aleksandra
Polychronis, Andreas
Uslu, Ruchan
Krzakowski, Maciej
Lee, Jong-Seok
Calabrò, Luana
Arén Frontera, Osvaldo
Xiong, Huiling
Bajars, Marcis
Ruisi, Mary
Barlesi, Fabrice
Abstract
In the JAVELIN Lung 200 trial, avelumab (anti-programmed death-ligand 1 [PD-L1] antibody) did not significantly prolong overall survival (OS) versus docetaxel in patients with platinum-treated PD-L1+ NSCLC. We report greater than 2-year follow-up data.
Subjects
Avelumab; Non–small cell lung cancer; PD-L1; Phase 3; Second-line
SDGs
Other Subjects
avelumab; docetaxel; monoclonal antibody; platinum; programmed death 1 ligand 1; clinical trial; controlled study; follow up; human; lung; lung tumor; phase 3 clinical trial; randomized controlled trial; tumor recurrence; Antibodies, Monoclonal, Humanized; B7-H1 Antigen; Docetaxel; Follow-Up Studies; Humans; Lung; Lung Neoplasms; Neoplasm Recurrence, Local; Platinum
Publisher
ELSEVIER SCIENCE INC
Type
journal article